ClinicalTrials.gg
CompletedNCT06979505Updated Feb 4, 2026

GV101 in Healthy Obese Participants

A Phase 2 interventional study of GV101 and GV101 placebo in Weight Management, sponsored by Graviton Bioscience Corporation. Completed at 20 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-02-04.

Sponsored by Graviton Bioscience Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
131
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The purpose of this trial is to evaluate the efficacy and safety of GV101 for weight loss over a range of doses in participants with obesity. The primary efficacy endpoint is the mean percent change in body weight from baseline at Week 16 in each treated group as compared with placebo.

02

Conditions studied

  • Weight Management
03

In context

Lead sponsor

Graviton Bioscience Corporation is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, aged ≥ 18 years and ≤ 70 years with ≥ 30.0 kg/m2 and ≤ 45.0 kg/m2 at the time of .
  2. Willing and able to provide written informed consent to participate in the trial, available for all visits, and able and willing to comply with all trial procedures.
  3. Except for obesity, otherwise healthy, as determined by the Investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests, and ECGs at screening.
  4. Have a stable body weight (\< 3 kg self-reported change during the previous 90 days) before screening.
  5. Willing to refrain from drastic changes in diet and physical activity regimen (those recommended via lifestyle counseling are acceptable).
  6. Participants of (any male who has not undergone vasectomy more than 6 months prior to the first dose of medicinal product [IMP] and any female who has not undergone bilateral oophorectomy, hysterectomy, total abdominal hysterectomy with bilateral salpingo-oophorectomy, bilateral tubal occlusion or ligation or who is not (a. A woman ≥55 years old not on hormone therapy, with amenorrhea for ≥12 months without an alternative medical cause, or b. A woman at least 55 years of age with a diagnosis of menopause prior to starting hormone replacement therapy or c. A woman > 40 and \< 55 years of age with an intact uterus, not on hormone therapy, who has cessation of menses for at least r1 year without an alternative cause, AND a follicle-stimulating hormone (FSH) >25 mIU/mL or d. A woman with premature ovarian failure confirmed by historical FSH levels in the postmenopausal range prior to initiating HRT, or by a documented irreversible medical condition causing permanent infertility.)), who are heterosexually active, must agree to use a combination of two of the following methods of (males must ensure their partner(s) use at least one method below to ensure at least two contraceptive methods are in place and must continue with this contraceptive plan for 90 days after the last dose of IMP; females must continue with this contraceptive plan for 28 days)
  7. Male participants with a pregnant partner (including those who have undergone a vasectomy) must agree to use a condom from the first dose of the IMP administration until at least 90 days after the last (if applicable) dose of the IMP.
  8. Male participants must agree not to donate sperm until 90 days after the last dose of IMP.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating.
  2. History of significant allergic reaction (e.g., immediate , significant respiratory and skin symptoms such as Steven Johnson syndrome) or hypersensitivity to any drug.
  3. History of gastrointestinal disease or surgery that may affect IMP absorption. A history of appendectomy or cholecystectomy is not exclusionary.
  4. Clinically significant physical examination abnormalities or clinically significant laboratory abnormalities at screening.
  5. Obesity induced by other endocrinologic disorder (e.g., Cushing's syndrome).
  6. Previous surgical treatment for obesity (excluding liposuction, if performed > 1 year before trial entry) and/or participants with recent (within 6 months) or planned endoscopic treatment for obesity.
  7. Current or history (within 90 days before screening) of treatment with medications that may cause significant weight gain or loss, including systemic (except for a short course of treatment, i.e., 7 - 10 days), tricyclic antidepressants, atypical antipsychotics and mood stabilizers (e.g., imipramine, amitriptyline, mirtazapine, paroxetine, phenelzine, chlorpromazine, thioridazine, clozapine, olanzapine, valproic acid and its derivatives, and lithium).
  8. Current participation (or within the last 90 days) in an organized weight reduction program or currently using or used within 90 days before screening: pramlintide, sibutramine, orlistat, zonisamide, topiramate, phentermine, naltrexone, bupropion, lorcaserin, metformin, or any GLP-1R and/or glucose-dependent insulinotropic polypeptide (GIP) agonists (either by prescription or as part of a clinical trial).
  9. Evidence of clinically significant hepatic or renal impairment, including but not limited to screening test results of and AST above 1.5x the , total above the ULN, history of Gilbert's syndrome or of elevated bilirubin, especially while fasting.
  10. History of clinically significant interval prolongation, or a QTcF interval of > 470 ms in females or of > 450 ms in males at screening.
  11. Clinically significant vital sign abnormalities at screening (systolic blood pressure [SBP] \< 90 or > 150 mm Hg, diastolic blood pressure [DBP] \< 50 or > 100 mm Hg, or heart rate [HR] \< 50 or > 100 bpm). Retesting is allowed at the discretion of the site Investigator or designee.
  12. Not willing to limit alcohol consumption to 2 drinks per day for males and 1 drink per day for females. History of alcohol misuse within 1 year prior to screening or regular alcohol consumption (more than 14 units per week [1 unit = 150 mL wine, 360 mL beer, or 45 mL 40% alcohol]) within 6 months prior to the screening visit.
  13. History of illicit drug misuse within 1 year prior to screening, or use of hard drugs (e.g., cocaine, phenylcyclohexyl piperidine [PCP], crack, opioid derivatives, and amphetamine derivatives) within 1 year prior to screening. A history of marijuana or tetrahydrocannabinol (THC)- product use within 30 days of enrollment and unwillingness to abstain from marijuana or the use of THC-containing products during the trial is also exclusionary. Stable daily CBD use is allowed (stable for > 30 days prior to randomization and planned continued stable use throughout the trial). Intermittent CBD use is not allowed.
  14. Participation in a clinical trial involving the administration of an or marketed drug or device use within 30 days or 5 half-lives, whichever is longer, before IMP administration; administration of a biological product in the context of a clinical trial within 90 days or 5 half-lives before IMP administration, whichever is longer, or concurrent participation in an experimental trial that does not involve the administration of an IMP or device use.
  15. Not willing to refrain from strenuous exercise or vigorous activity (e.g., heavy lifting, weight training, yard work in hot weather, and aerobics) for 72 hours before each blood collection for clinical laboratory tests.
  16. Use of drugs and foods including inhibitors or inducers (Table 10), UGT1A1 substrates and inhibitors, daily use of medications that are substrates of CYP2C8, CYP2C9, or CYP2C19 and have a narrow therapeutic index.
  17. The following test results:

    1. Positive , positive Ab with non-negative HCV RNA test, or positive test at screening
    2. Calculated estimated (eGFR) \< 60 mL/min/1.73 m2 at screening
    3. Positive pregnancy test at any time from screening onwards
    4. Positive drug test at screening
    5. ≥ 6.5% and/or known history of type 1 or type 2 diabetes mellitus, other forms of diabetes like LADA, MODY and secondary diabetes.

      Note: Patients with h/o gestational diabetes (but no diagnosis of T2DM post partum) can qualify.

    6. Thyroid stimulating hormone (TSH) > 6 mIU/L or \< 0.4 mIU/L at screening
    7. Fasting triglycerides ≥ 5.65 mmol/L (i.e., 500 mg/dL)
    8. ALT or AST above 1.5x the ULN, total bilirubin above the ULN at screening
    9. count \< 150,000 platelets/mL
  18. Participant unwilling or unable to abstain from using nicotine or tobacco, cigars, cigarettes, e-cigarettes/vaping, pipes, or nicotine patches for 45 minutes prior to trial visits.
  19. History or evidence of any other clinically significant disorder, condition, or disease or any other reason that, in the opinion of the Investigator or physician, would pose a risk to participant safety or interfere with the trial evaluation, procedures, or completion.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
131 participants (actual)

Study arms

  • Experimental
    GV101 low dose

    Drug: GV101

  • Experimental
    GV101 high dose

    Drug: GV101

  • Placebo comparator
    GV101 matched placebo

    Drug: GV101 placebo

Interventions

  • DrugGV101

    GV101 suspension

  • DrugGV101 placebo

    GV101 placebo suspension

06

What researchers measure

Primary outcomes

  1. Mean percent change in body weight from baseline at Week 16 in each treated group as compared with placebo

    Time frame: 16 weeks

07

Study locations

20 sites
  • Lakeview Clinical Research, LLC
    Guntersville, Alabama 35976, United States
  • Arizona Clinical Trials
    Tucson, Arizona 85712, United States
  • Catalina Research Institute, LLC
    Montclair, California 91763, United States
  • Encompass Clinical Research
    Spring Valley, California 91978, United States
  • Louisville Metabolic and Atherosclerosis Research Center (L-MARC)
    Louisville, Kentucky 40213, United States
  • Tandem Clinical Research
    Marrero, Louisiana 70072, United States
  • Study Metrix Research
    City of Saint Peters, Missouri 63303, United States
  • Kansas City Research Institute
    Kansas City, Missouri 64131, United States
  • Mercury Street Medical
    Butte, Montana 59701, United States
  • Hassman Research Institute
    Berlin, New Jersey 08009, United States
  • Coastal Research Institute, LLC
    Fayetteville, North Carolina 28304, United States
  • Lillestol Research, LLC
    Fargo, North Dakota 58104, United States
  • Velocity Clinical Research - Cleveland
    Cleveland, Ohio 44122, United States
  • Velocity Clinical Research - Dallas
    Dallas, Texas 75230, United States
  • Advanced Research Institute - Ogden
    Ogden, Utah 84405, United States
  • Chrysalis Clinical Research
    St. George, Utah 84790, United States
  • Hadassah Medical Center Ein Karem
    Jerusalem, Israel, Israel
  • Hasharon Hospital
    Petah Tikva, Israel, Israel
  • Rabin Medical Center, Beilinson Hospital
    Petah Tikva, Israel, Israel
  • Sheba Medical Center
    Tel Litwinsky, Israel, Israel
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2025 to primary completion in Jan 2026, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2025
First posted
May 20, 2025
StartActual
Jun 30, 2025
Primary completionActual
Jan 28, 2026
CompletionActual
Jan 28, 2026
Last update
Feb 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06979505
Lead sponsor
Graviton Bioscience Corporation
Responsible party
Sponsor
First posted
May 20, 2025
Start date
Jun 30, 2025
Primary completion
Jan 28, 2026
Completion
Jan 28, 2026
Last update
Feb 4, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GV101

Start the discussion